HPV Vaccine and Cervical Cancer Prevention

Dear Colleagues,

Cervical cancer is a serious public health problem and represents the fourth most common cancer in women globally. The highest rates of cervical cancer incidence and mortality are in low- and middle-income countries driven by inequalities of access to HPV vaccination, screening and treatment services, and socioeconomic determinants. As demonstrated in many published clinical trials and epidemiological studies, HPV vaccination, screening, and the treatment of pre-invasive lesions are effective ways to prevent cervical cancer. In addition, cervical cancer can be cured if diagnosed and treated at an early stage of the disease. A commitment to eliminate cervical cancer as a public health problem follows the WHO global strategy with three targets (90% of girls vaccinated against HPV by age 15, 70% of women screened with a high-quality test, HPV test as primary screening, instead of conventional or liquid cytopathological examination, by ages 35 and 45, and 90% of women with cervical disease receiving treatment) to be achieved in 2030.

I am pleased to invite you to submit a paper to this Special Issue, titled “HPV Vaccine and Cervical Cancer Prevention”, with evidence-based recommendations focused on the current state of the art, health assessment, screening procedures, early diagnosis, long term outcomes, socioeconomic burden, etc.

This Special Issue aims to publish original review and research articles, including translational research and clinical and observational trials.

Research areas may include, but are not limited to, the following:

• Modeling estimates of HPV vaccination impact;
• Public awareness of HPV vaccination;
• Access to HPV vaccination;
• Information and services to prevention and control of cervical cancer;
• Impact of HPV vaccination;
• Screening in HPV vaccinated women;
• Socioeconomic burden of HPV vaccination.

I look forward to receiving your contributions.

Dr. Andreia Cristina de Melo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Healthcare is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• HPV vaccination
• screening
• cervical cancer
• prevention